Definium Therapeutics Overview
Definium Therapeutics Target Price
Analysts' 12-month price predictions for DFTX.
Get informed when a big investor buys or sells
+ FollowShare Price
$23.59
Average Target Price
$38.33
62.5% upside
62.5% upside6 analysts in the last 4 months
High: $49 | Low: $25
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-08 | Piper SandlerDavid Amsellem | $48 | 103.5% upside |  |
| 2026-04-23 | Oppenheimer | $40 | 69.6% upside | |
| 2026-04-16 | Stifel NicolausPaul Matteis | $30 | 27.2% upside | |
| 2026-04-16 | Canaccord GenuitySumant Kulkarni | $38 | 61.1% upside | |
| 2026-04-10 | Piper Sandler | $49 | 107.7% upside | |
| 2026-02-23 | Wolfe Research | $25 | 6% upside | |
| 2026-01-29 | Jefferies | $30 | 27.2% upside | |
| 2026-01-29 | Robert W. Baird | $37 | 56.8% upside | |
| 2026-01-23 | RBC Capital | $36 | 52.6% upside | |
| 2025-10-13 | NeedhamAmi Fadia | $28 | 18.7% upside | |
| 2025-03-07 | Robert W. Baird | $16 |  32.2% downside | |
| 2024-09-16 | Canaccord GenuitySumart Kulkami | $14 | 40.7% downside | |
| 2024-06-05 | RBC CapitalBrian Abrahams | $22 | 6.7% downside | |
| 2024-05-13 | OppenheimerFrancois Brisebois | $20 | 15.2% downside | |
| 2022-11-16 | RBC Capital | $5 | 78.8% downside | |